A Clinical Study of Tranilast in the Treatment of Sarcoidosis
NCT03528070 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 56
Last updated 2018-05-17
Summary
56 patients with sarcoidosis will be selected to receive treatment of tranilast.The investigators can analyse the changes in the thickness and area of skin lesions before and after treatment as well as other involved organs nodule size changes to determine the efficacy and safety of drugs.
Conditions
- Sarcoidosis
Interventions
- DRUG
-
Tranilast
Subjects will be treated with tranilast
Sponsors & Collaborators
-
The First Affiliated Hospital with Nanjing Medical University
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-05-31
- Primary Completion
- 2020-05-31
- Completion
- 2020-12-31
More Related Trials
-
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06470048 ·Status: RECRUITING ·Phase: PHASE2
-
A Prospective Cohort Study on Primary Cutaneous Amyloidosis
NCT06998875 ·Status: RECRUITING ·Phase: PHASE4
-
Lenalidomide in the Treatment of Refractory Cutaneous Dermatomyositis
NCT05488327 ·Status: UNKNOWN ·Phase: NA
-
A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)
NCT00442611 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
3T Therapy in the Treatment of MDA5-positive Dermatomyositis
NCT06438679 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE4
-
The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis
NCT00794274 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Platform Clinical Study for Conquering Scleroderma
NCT06195072 ·Status: RECRUITING ·Phase: PHASE2
-
IL1-TRAP, Rilonacept, in Systemic Sclerosis
NCT01538719 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of MT-0551 in Patients With Systemic Sclerosis
NCT05198557 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Worldwide Sarcoidosis Research Study
NCT01610843 ·Status: COMPLETED
-
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
NCT05270668 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment Project
NCT05316805 ·Status: RECRUITING
-
Longitudinal Spatial Frequency Domain Imaging Study
NCT05672992 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms
NCT05559580 ·Status: COMPLETED ·Phase: PHASE2
-
RCT of Nintedanib in Fibrotic Sarcoidosis
NCT06479603 ·Status: RECRUITING ·Phase: PHASE4
-
Risk Indicators of Sarcoidosis Evolution-Unified Protocol
NCT05567133 ·Status: RECRUITING
-
Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the CARNEY Complex (CNC)
NCT00668291 ·Status: COMPLETED
-
Clinical Study of Divozilimab in Patients With Systemic Scleroderma
NCT05726630 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
The Efficacy and Safety of JAK Inhibitor in the Treatment of Anti-MDA5 Antibody-positive Dermatomyositis Patients
NCT04966884 ·Status: UNKNOWN ·Phase: PHASE4
-
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
NCT01309997 ·Status: COMPLETED ·Phase: PHASE2
-
A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy
NCT00936546 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Imatinib in Systemic Sclerosis
NCT00506831 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome.
NCT04904146 ·Status: RECRUITING
-
Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis
NCT06119490 ·Status: RECRUITING ·Phase: EARLY_PHASE1